18 completed, 5 active not recruiting, 4 recruiting, 3 terminated. 19 Phase 2, 4 Phase 3, 3 Phase 1, 2 Not applicable, 2 Phase 4.
Follow metreleptin: new trials by email Literature Review of metreleptin trials Research Report on metreleptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy Metreleptin - Generalized Lipodystrophy | Phase 3 | Terminated | Amryt Pharma | 1 | 2025-05-23 | 2026-07-22 |
| Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy Metreleptin - Familial Partial Lipodystrophy | Phase 3 | Recruiting | Chiesi Farmaceutici S.p.A. | 24 | 2024-10-14 | 2026-07-16 |
| Metreleptin in Anorexia Nervosa Metreleptin, Sodium chloride - Anorexia Nervosa | Phase 2 | Recruiting | Gabriella Milos | 50 | 2024-05-31 | 2026-07-29 |
| Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy Metreleptin - Partial Lipodystrophy | Phase 4 | Recruiting | Amryt Pharma | 12 | 2024-02-08 | 2025-07-03 |
| Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL) Metreleptin - Lipomatosis, Multiple Symmetrical | Phase 2 | Active not recruiting | University of Michigan | 4 | 2023-08-01 | 2025-06-12 |
| Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL metreleptin, Placebo - Partial Lipodystrophy | Phase 3 | Active not recruiting | Chiesi Farmaceutici S.p.A. | 69 | 2021-12-17 | 2026-06-15 |
| The Effects of Metreleptin in Congenital Leptin Deficiency Metreleptin - Congenital Leptin Deficiency (Disorder) | Completed | Northwestern University | 2 | 2019-06-20 | 2021-12-30 | |
| Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy Metreleptin - Generalized Lipodystrophy | Phase 4 | Completed | Aegerion Pharmaceuticals, Inc. | 11 | 2018-11-14 | 2025-11-26 |
| MEASuRE: Metreleptin Effectiveness And Safety Registry Metreleptin - Generalised Lipodystrophy, Partial Lipodystrophy | Recruiting | Chiesi Farmaceutici S.p.A. | 100 | 2016-10-11 | 2026-07-16 | |
| CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Metreleptin - Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis | Phase 2 | Completed | University of Michigan | 11 | 2015-09-29 | 2020-11-24 |
| Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Metreleptin - Diabetes, Lipodystrophy | Phase 2 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 29 | 2014-10-14 | 2026-10-19 |
| Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Metreleptin - Lipodystrophy, Diabetes | Phase 3 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 24 | 2014-10-09 | 2026-09-22 |
| Short-term Effects of Leptin in People With Lipodystrophy Metreleptin - Lipodystrophy | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 25 | 2013-01-26 | 2019-11-13 |
| Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Metreleptin - Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis | Phase 2 | Completed | University of Michigan | 23 | 2012-10-08 | 2017-06-14 |
| Effects of Metreleptin in Type 1 Diabetes Mellitus Leptin - Type 1 Diabetes | Phase 1 | Terminated | University of Texas Southwestern Medical Center | 8 | 2010-09-01 | 2019-08-28 |
| Study of Leptin for the Treatment of Hypothalamic Amenorrhea r-metHuLeptin, Oral Contraceptive Pills (OCPs), Placebo - Amenorrhea | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 20 | 2010-04-01 | 2017-05-17 |
| Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin Placebo, Pramlintide and Metreleptin - Obesity | Phase 2 | Completed | AstraZeneca | 274 | 2008-11-01 | 2015-04-15 |
| Leptin in the Maintenance of Reduced Body Weight Leptin, Placebo - Obesity | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 24 | 2008-07-01 | 2017-04-07 |
| Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects pramlintide acetate, metreleptin, placebo-P - Overweight, Obesity | Phase 2 | Completed | AstraZeneca | 636 | 2008-04-01 | 2015-04-15 |
| Trial of Leptin Administration After Roux-en-Y Gastric Bypass Leptin, Placebo - Overweight | Phase 1 / Phase 2 | Completed | Columbia University | 31 | 2008-04-01 | 2015-11-16 |
Showing 20 of 31. Sign in to see all of them.
Lipodystrophy (9) · Diabetes Mellitus (8) · Obesity (8) · Hypertriglyceridemia (6) · Lipodystrophy, Congenital Generalized (3) · Lipodystrophy, Partial, Acquired (3) · Non-alcoholic Fatty Liver Disease (3) · Overweight (3) · Hyperlipidemias (2) · Insulin Resistance (2) · Lipodystrophy, Familial Partial (2) · Metabolic Syndrome (2) · Amenorrhea (1) · Anorexia Nervosa (1) · Depression (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · AstraZeneca (3) · Beth Israel Deaconess Medical Center (3) · Chiesi Farmaceutici S.p.A. (3) · University of Michigan (3) · Amryt Pharma (2) · Columbia University (2) · University of Miami (2) · University of Texas Southwestern Medical Center (2) · Aegerion Pharmaceuticals, Inc. (1) · Baylor College of Medicine (1) · Bristol-Myers Squibb (1) · Elif Oral (1) · Gabriella Milos (1) · Northwestern University (1)
United States (27) · France (3) · Germany (3) · Italy (3) · Belgium (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Chile (1) · Israel (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1)
Rebecca J Brown, M.D. (4) · Abhimanyu Garg, M.D. (2) · Elif A Oral, MD (2) · Julio Licinio, MD (2) · Ashok Balasubramanyam, MD (1) · Christos S Mantzoros, MD (1) · Christos S Mantzoros, MD, DSc (1) · Christos S Mantzoros, MD, ScD (1) · Elif A Oral, MD, MS (1) · Elif Oral (1) · Janet Boylan (1) · Jean Chan, MD (1) · Judith Korner, MD,PhD (1) · Lisa Neff, MD (1)
PMID 26589105, PMID 28324110, PMID 34677608, PMID 31194872, PMID 19889232, PMID 21070531, PMID 33051459, PMID 34223895, PMID 35291351, PMID 37595266, PMID 39097160, PMID 10523015, PMID 11443202, PMID 15070752, PMID 15713712, PMID 15949871, PMID 17517446, PMID 17684509, PMID 17986612, PMID 18726828, PMID 18769731, PMID 18854428, PMID 19727665, PMID 20101893, PMID 21464293, PMID 21593494, PMID 21660636, PMID 21741057, PMID 21917874, PMID 22068254, PMID 22542724, PMID 22965160, PMID 23193213, PMID 23382191, PMID 23439261, PMID 23969187, PMID 24703486, PMID 24926953, PMID 25070319, PMID 25148234, PMID 25540981, PMID 25734254, PMID 26900642, PMID 27642538, PMID 29723161, PMID 29920214, PMID 32191645, PMID 32573497, PMID 33045195, PMID 33890058
M01RR001032 (2), R01DK058785 (1), R01DK058851 (1), R01DK064773 (1), R01DK079929 (1), R01DK088114 (1), R03DK074488 (1), R21DK081050 (1), R34HD048526 (1), UL1RR024156 (1)